NDAORALTABLET
Approved
Aug 2005
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Clinical Trials
1
Data completeness
5/8 — Partial
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ACTOPLUS MET is a fixed-dose oral combination of pioglitazone (a thiazolidinedione PPARγ agonist) and metformin (a biguanide), approved for type 2 diabetes mellitus. It combines insulin sensitization in peripheral tissues and liver with hepatic glucose suppression and improved peripheral glucose uptake. The dual mechanism targets insulin resistance through complementary pathways without inducing hypoglycemia.
$0.131MPart D
LOE ApproachingDeclining
<0.1% of type 2 diabetes combination oral market
2.8 years to LOEProduct is in endgame phase with minimal market presence; brand team downsizing is typical at this stage.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Pioglitazone for the Treatment of Major Depressive Disorder Comorbid With Metabolic Syndrome
Started Apr 2008
23 enrolled
Depressive Disorder, MajorMetabolic Syndrome X
Why This Matters for Your Career
Worked on ACTOPLUS MET at Takeda? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.